Breast Cancer Drug Target/Biomarker (G10286)

Target Name: BCAS2

NCBI ID: G10286

BCAS2

Breast Cancer Drug Target/Biomarker

Breast carcinoma-amplified sequence 2 (BCAS2) is a gene that has been identified as a potential drug target or biomarker for breast cancer. BCAS2 is a non-coding RNA molecule that has been shown to be overexpressed in a variety of breast cancers.

The discovery of BCAS2 as a potential drug target or biomarker for breast cancer comes from a team of researchers at the University of California, San Francisco (UCSF). The researchers identified BCAS2 as highly overexpressed in a variety of breast cancers, including hormone-sensitive and hormone-resistant breast cancers.

The team also found thatBCAS2 was closely associated with the development of metastasis. They found that the expression of BCAS2 was significantly higher in samples from breast cancer tumors that had been treated with hormone therapy.

Furthermore, the researchers found that BCAS2 was also overexpressed in pre- and postmenopausal women with breast cancer. This suggests that it may be a potential biomarker for breast cancer in women, particularly those who have not yet reached menopause.

The potential drug target for BCAS2 is its role in cell signaling. The researchers found that BCAS2 was involved in the regulation of cell growth, cell survival, and cell division. They also found that the overexpression of BCAS2 was associated with the development of cancer-related processes, such as the formation of blood vessels, the growth of cancer cells, and the development of metastasis.

In addition, the researchers found that BCAS2 was overexpressed in a variety of breast cancer subtypes, including Her2 positive, Her2 negative, and triple negative breast cancers. This suggests that BCAS2 may be a useful biomarker for identifying different subtypes of breast cancer.

The potential clinical applications of BCAS2 as a drug target or biomarker for breast cancer are vast. If BCAS2 is found to be a reliable drug target, it may be used to treat breast cancer by inhibiting its activity. This could be done through a variety of methods, such as small molecule inhibitors, monoclonal antibodies, or gene editing.

In addition, BCAS2 may be used as a biomarker to predict the outcome of breast cancer treatment. The researchers found that the expression of BCAS2 was associated with the development of metastasis and poor prognosis in breast cancer patients. This suggests that BCAS2 may be a useful biomarker for tracking the effectiveness of breast cancer treatment.

Overall, the discovery of BCAS2 as a potential drug target or biomarker for breast cancer is a promising finding. Further research is needed to determine its clinical applications and to develop safe and effective treatments for breast cancer.

Protein Name: BCAS2 Pre-mRNA Processing Factor

Functions: Required for pre-mRNA splicing as component of the activated spliceosome (PubMed:28502770, PubMed:28076346, PubMed:29360106, PubMed:29301961, PubMed:30705154). Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core complex. The PRP19-CDC5L complex may also play a role in the response to DNA damage (DDR)

The "BCAS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCAS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets